The Hikma Pharmaceuticals Plc Board is recommending an interim dividend of 38 cents per share (H1 2025: 36 cents per share). The interim dividend will be paid on 17 September 2026 to eligible shareholders on the register at the close of business on 14 August 2026.
Other financial highlights include:
o Branded revenue of $502 million, up 15%
o Injectables revenue of $685 million, in line with H1 2025
o Hikma Rx revenue of $520 million, in line with H1 2025
Group core operating profit of $405 million, up 9%
o Branded core operating profit up 23% (20% in constant currency), with core operating margin of 32.5%
o Injectables core operating profit down 8% (down 9% in constant currency) and core operating margin of 27.6%
o Hikma Rx core operating profit up 16% with 20.6% core operating margin
o Reported Group operating profit up 30%, primarily due to a lower comparator in H1 2025, which was impacted by the non-core legal settlement related to sodium oxybate
Robust balance sheet, cashflow and dividend growth
o Cashflow from operating activities of $214 million (H1 2025: $161 million)
o Net debt to core EBITDA of 1.9x at 30 June 2026 (31 December 2025: 1.6x)
o $250 million share buyback progressing well with $227 million worth of shares purchased as at 5 August 2026
